Virus-like Particles as Preventive and Therapeutic Cancer Vaccines

Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native virus structure without being infectious. VLPs, similarly to wild type viruses, are able to efficiently target and activate dendritic cells (DCs) triggering the B and T cell immunities. Therefore, VLPs hold great promise for the development of effective and affordable vaccines in infectious diseases and cancers. Vaccine formulations based on VLPs, compared to other nanoparticles, have the advantage of incorporating multiple antigens derived from different proteins. Moreover, such antigens can be functionalized by chemical modifications without affecting the structural conformation or the antigenicity. This review summarizes the current status of preventive and therapeutic VLP-based vaccines developed against human oncoviruses as well as cancers.

Automated summary

Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the structure of native viruses. They are able to efficiently activate the immune response and hold promise for the development of vaccines against infectious diseases and cancers. VLP-based vaccine formulations have the advantage of incorporating multiple antigens and can be modified without affecting their structure or antigenicity.